These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 27133774)

  • 1. Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
    Cristea S; Sage J
    J Thorac Oncol; 2016 Aug; 11(8):1233-1241. PubMed ID: 27133774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Raf/MEK/ERK pathway in pituitary adenomas.
    Suojun Z; Feng W; Dongsheng G; Ting L
    Eur J Cancer; 2012 Feb; 48(3):389-95. PubMed ID: 22119203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
    Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
    Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New perspectives on targeting RAF, MEK and ERK in melanoma.
    Dumaz N; Lebbé C
    Curr Opin Oncol; 2021 Mar; 33(2):120-126. PubMed ID: 33332926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.
    Wong KK
    Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):28-35. PubMed ID: 19149686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways.
    García-Pérez AI; Galeano E; Nieto E; Estañ MC; Sancho P
    Leuk Res; 2014 Jul; 38(7):795-803. PubMed ID: 24811390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer.
    Chen Y; Nowak I; Huang J; Keng PC; Sun H; Xu H; Wei G; Lee SO
    J Thorac Oncol; 2014 Jan; 9(1):50-8. PubMed ID: 24346093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibronectin-induced proliferation in thyroid cells is mediated by alphavbeta3 integrin through Ras/Raf-1/MEK/ERK and calcium/CaMKII signals.
    Illario M; Cavallo AL; Monaco S; Di Vito E; Mueller F; Marzano LA; Troncone G; Fenzi G; Rossi G; Vitale M
    J Clin Endocrinol Metab; 2005 May; 90(5):2865-73. PubMed ID: 15687337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562.
    Chan KT; Li K; Liu SL; Chu KH; Toh M; Xie WD
    Cancer Lett; 2010 Mar; 289(1):46-52. PubMed ID: 19700240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
    Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI; Solit DB
    Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.
    Adjei AA
    Clin Lung Cancer; 2005 Nov; 7(3):221-3. PubMed ID: 16354319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MAPK pathway across different malignancies: a new perspective.
    Burotto M; Chiou VL; Lee JM; Kohn EC
    Cancer; 2014 Nov; 120(22):3446-56. PubMed ID: 24948110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.